Updated recommendations on systemic treatment of non-small cell lung cancer and malignant pleural mesothelioma;Uaktualnione zalecenia dotyczace systemowego leczenia niedrobnokomó rkowego raka płuca i złośliwego miedzybłoniaka opłucnej

Pneumonologia i Alergologia Polska

Volumn 78, Issue 6, 2010, Pages 418-431

  Jassem, Jacek ^a   Biernat, Wojciech ^a   Drosik, Kazimierz ^b   Dziadziuszko, Rafał ^a   Kordek, Radzisław ^c   Kozielski, Jerzy ^d   Kowalski, Dariusz M ^e   Krzakowski, Maciej ^e   Nikliński, Jacek ^f   Olszewski, Włodzimierz ^e   Orłowski, Tadeusz ^g   Ramlau, Rodryg ^h   Roszkowski Śliz, Kazimierz ^g   Rzyman, Witold ^a  

^a Uniwersytet Medyczny   (Poland)

^b Wojewódzki Ośrodek Onkologiczny w Opolu ^*  (Poland)

^c MEDICAL UNIVERSITY OF LODZ   (Poland)

^d l ski Uniwersytet Medyczny   (Poland)

^e INSTITUTE OF ONCOLOGY   (Poland)

^f MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^g INSTYTUT GRU LICY I CHORÓB P UC   (Poland)

^h GREATER POLAND CANCER CENTRE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CANCER STAGING; CONSENSUS; CONSENSUS DEVELOPMENT; DISEASE COURSE; HUMAN; LUNG NON SMALL CELL CANCER; MESOTHELIOMA; METHODOLOGY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PLEURA TUMOR; POLAND; PRACTICE GUIDELINE; RADIOSURGERY; RADIOTHERAPY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; CONSENSUS; CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; DISEASE PROGRESSION; HUMANS; MESOTHELIOMA; NEOPLASM STAGING; PLEURAL NEOPLASMS; POLAND; PRACTICE GUIDELINES AS TOPIC; RADIOSURGERY; RADIOTHERAPY;

EID: 78649603195     PISSN: 08677077     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (130)

1. Didkowska J., Wojciechowska U., Tarkowski W. i wsp. Nowotwory złośliwe w Polsce w 2006 roku. Warszawa: Centrum Onkologii - Instytut, 2008.
2. Bülzebruck H., Bopp R., Drings P. i wsp. New aspects in the staging of lung cancer: prospective validation of the International Union Against Cancer TNM classification. Cancer 1992; 70: 1102-1110.
3. Naruke T., Goya T., Tsuchiya R. i wsp. Prognosis and survival in resected lung carcinoma based on the international staging system. J. Thorac. Cardiovasc. Surg. 1998; 96: 440-447.
4. Jassem J., Skokowski J., Dziadziuszko R. i wsp. Results of surgical treatment of non-small cell lung cancer: validation of the new postoperative pathologic TNM classification. J. Thorac. Cardiovasc. Surg. 2000; 119: 1141-1146.
5. Jassem J., Drosik K., Dziadziuszko R. i wsp. Zalecenia dotyczace systemowego leczenia niedrobnokomórkowego raka płuca i złośliwego miedzybłoniaka opłucnej: Konferencja okragłego stołu. Nowotwory J. Oncol. 2005; 55: 160-166.
6. Jassem J., Drosik K., Dziadziuszko R. i wsp. Systemowe leczenie niedrobnokomórkowego raka płuca i złośliwego miedzybłoniaka opłucnej: uaktualnione zalecenia oparte na wynikach wiarygodnych badań klinicznych. Nowotwory J. Oncol. 2007; 57: 71-78.
7. Travis W.D., Brambilla E., Muller-Hermelink H.K., Harris C.C. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC; 2004.
8. Pao W., Miller V.A. Epidermal growth factor receptor mutations, smallmolecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J. Clin. Oncol. 2005; 23: 2556-2568.
9. Scagliotti G.V., Parikh P., von Pawel J. i wsp. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy- naive patients with advanced-stage non-small-cell lung cancer. J. Clin. Oncol. 2008; 26: 3543-3551.
10. Sequist L.V., Bell D.W., Lynch T.J., Haber D.A. Molecular predictors of response to epidermal growth factor receptor antagonists in non-smallcell lung cancer. J. Clin. Oncol. 2007; 25: 587-595.
11. Johnson D.H., Fehrenbacher L., Novotny W.F. i wsp. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. 2004; 22: 2184-2191.
12. Barlesi F., Pinot D., Legoffic A. i wsp. Positive thyroid transcription factor 1 staining strongly correlates with survival of patients with adenocarcinoma of the lung. Br. J. Cancer 2005; 93: 450-452.
13. Camilo R., Capelozzi V.L., Siqueira S.A., Del Carlo B.F. Expression of p63, keratin 5/6, keratin 7, and surfactant-A in nonsmall cell lung carcinomas. Hum. Pathol. 2006; 37: 542-546.
14. Johansson L. Histopathologic classification of lung cancer: Relevance of cytokeratin and TTF-1 immunophenotyping. Ann. Diagn. Pathol. 2004; 8: 259-267.
15. Kalhor N., Zander D.S., Liu J. TTF-1 and p63 for distinguishing pulmonary small-cell carcinoma from poorly differentiated squamous cell carcinoma in previously pap-stained cytologic material. Mod. Pathol. 2006; 19: 1117-1123.
16. Kargi A., Gurel D., Tuna B. The diagnostic value of TTF-1, CK 5/6, and p63 immunostaining in classification of lung carcinomas. Apel. Immunohistochem. Mol. Morphol. 2007; 15: 415-420.
17. Khayyata S., Yun S., Pasha T. i wsp. Value of P63 and CK5/6 in distinguishing squamous cell carcinoma from adenocarcinoma in lung fine-needle aspiration specimens. Diagn. Cytopathol. 2009; 37: 178-183.
18. Sturm N., Lantuejoul S., Laverriere M.H. i wsp. Thyroid transcription factor 1 and cytokeratins 1, 5, 10, 14 (34betaE12) expression in basaloid and large-cell neuroendocrine carcinomas of the lung. Hum. Pathol. 2001; 32: 918-925.
19. Tan D., Li Q., Deeb G. i wsp. Thyroid transcription factor-1 expression prevalence and its clinical implications in non-small cell lung cancer: a high-throughput tissue microarray and immunohistochemistry study. Hum. Pathol. 2003; 34: 597-604.
20. Nicholson A.G., Gonzalez D., Shah P. i wsp. Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis. J. Thorac. Oncol. 2010 (w druku).
21. Aida S., Shimazaki H., Sato K. i wsp. Prognostic analysis of pulmonary adenocarcinoma subclassification with special consideration of papillary and bronchioloalveolar types. Histopathology 2004; 45: 468-476.
22. Yokose T., Suzuki K., Nagai K. i wsp. Favorable and unfavorable morphological prognostic factors in peripheral adenocarcinoma of the lung 3 cm or less in diameter. Lung Cancer 2000; 29: 179-188.
23. Stahel R.A., Weder W., Felip E. Malignant pleural mesothelioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol. 2009; 20 (supl. 4): 73-75.
24. Butnor K.J., Sporn T.A., Ordonez N.G. Recommendations for the reporting of pleural mesothelioma. Virchows Arch. 2007; 450: 15-23.
25. Churg A., Colby T.V., Cagle P. i wsp. The separation of benign and malignant mesothelial proliferations. Am. J. Surg. Pathol. 2000; 24: 1183-1200.
26. Rosell R., Gomez-Codina J., Camps C. i wsp. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N. Engl. J. Med. 1994; 330: 153-158.
27. Roth J.A., Fosella F., Komaki R. i wsp. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J. Natl. Cancer Inst. 1994; 86: 673-680.
28. Depierre A., Milleron B., Moro-Sibilot D. i wsp. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-smallcell lung cancer. J. Clin. Oncol. 2002; 20: 247-253.
29. Gilligan D., Nicolson M., Smith I. i wsp. Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review. Lancet 2007; 369: 1929-1937.
30. Pisters K., Vallieres E., Bunn P.A. Jr. i wsp. Surgery alone or surgery plus induction (ind) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): Follow-up on a phase III trial. J. Clin. Oncol. 2007; 25 (supl.): 389s (abstrakt).
31. Scagliotti G.V., Pastorino U., Vansteenkiste J.F. i wsp. A phase III randomized study of surgery alone or surgery plus preoperative gemcitabine-cisplatin in early-stage non-small cell lung cancer (NSCLC): follow-up data on Ch.E.S.T. J. Clin. Oncol. 2008; 26 (supl.): 399 (abstrakt).
32. Burnett S., Stewart L.A., Rydzewska L. A systematic review and metaanalysis of the literature: chemotherapy and surgery versus surgery alone in non-small cell lung cancer. J. Thorac. Oncol. 2006; 1: 611-621.
33. Felip E., Massuti B., Alonso G. i wsp. Surgery (S) alone, preoperative (preop) paclitaxel/carboplatin (PC) chemotherapy followed by S, or S followed by adjuvant (adj) PC chemotherapy in early-stage non-small cell lung cancer (NSCLC): results of the NATCH. J. Clin. Oncol. 2009; 27 (supl.): 382s (abstrakt).
34. Lim E., Harris G., Patel A. i wsp. Preoperative versus postoperative chemotherapy in patients with resectable non-small cell lung cancer: systematic review and indirect comparison of randomized trials. J. Clin. Oncol. 2008; 26 (supl.): 408 (abstrakt).
35. van Meerbeeck J.P., Kramer G.W., Van Schil P.E. i wsp. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J. Natl. Cancer Inst. 2007; 99: 442-450.
36. Albain K.S., Swann R.S., Rusch V.W. i wsp. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 2009; 374: 379-386.
37. Rusch V.W., Giroux D.J., Kraut M.J. i wsp. Induction chemoradiation and surgical resection for superior sulcus non-small cell lung carcinomas: long-term results of Southwest Oncology Group trial 9416 (Intergroup Trial 0160). J. Clin. Oncol. 2007; 25: 313-318.
38. Kunitoh H., Kato H., Tsuboi M. i wsp. Phase II trial of preoperative chemoradiotherapy followed by surgical resection in patients with superior sulcus non-small cell lung cancers: report of Japan Clinical Oncology Group trial 9806. J. Clin. Oncol. 2008; 26: 644-649.
39. Kappers I., van Sandick J.W., Burgers J.A. i wsp. Results of combined modality treatment in patients with non-small-cell lung cancer of the superior sulcus and the rationale for surgical resection. Eur. J. Cardiothorac. Surg. 2009; 36: 741-746.
40. Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized trials. Br. Med. J. 1995; 311: 899-909.
41. Keller S.M., Adak S., Wagner H. i wsp. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small cell lung cancer. N. Engl. J. Med. 2000; 343: 1217-1222.
42. Waller D., Peake M.D., Stephens R.J. i wsp. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. Eur. J. Cardiothorac. Surg. 2004; 26: 173-182.
43. Scagliotti G.V., Fossati R., Torri V. i wsp. Randomized study of adjuvant chemotherapy for completely resected stage I, II or IIIA non-small cell lung cancer. J. Natl. Cancer Inst. 2003; 95: 1453-1461.
44. The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. N. Engl. J. Med. 2004; 350: 351-360.
45. Winton T., Livingston R., Johnson D. i wsp. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N. Engl. J. Med. 2005; 352: 2589-2597.
46. Strauss G.M., Herndon II J.E., Maddaus M.A. i wsp. Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): Update of Cancer and Leukemia Group B (CALGB) protocol 9633. J. Clin. Oncol. 2006; 24 (supl.): 365s (abstrakt).
47. Kato H., Ichinose Y., Ohta M. i wsp. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 2004; 350: 1713-1721.
48. Douillard J.-Y., Rosell R., De Lena M. i wsp. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006; 7: 719-27.
49. Pignon J.P., Tribodet H., Scagliotti G.V. i wsp. Lung Adjuvant Cisplatin Evaluation (LACE): a pooled analysis by the LACE Collaborative Group. J. Clin. Oncol. 2008; 26: 3552-3559.
50. Burdett S., Arriagada R., Lesley S. i wsp. Chemotherapy (CT) in addition to surgery or surgery plus radiotherapy (RT) in nonsmall cell lung cancer (NSCLC): Two meta-analyses using individual patient data (IPD) from randomized controlled trials (RCTs) J. Thorac. Oncol. 2007; 2 (supl.): 366.
51. Butts C.A., Ding K., Seymour L. i wsp. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small cell lung cancer: updated survival analysis of JBR-10. J. Clin. Oncol. 2010; 28: 29-34.
52. Hotta K., Matsuo K., Ueoka H. i wsp. Role of adjuvant chemotherapy in patients with resected non-small cell lung cancer: reappraisal with a meta-analysis of randomized controlled trials. J. Clin. Oncol. 2004; 22: 3860-3867.
53. Alam N., Shepherd F.A., Winton T. i wsp. Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer: an analysis of National Cancer Institute of Canada and Intergroup Trial JBR.10 and a review of the literature. Lung Cancer 2005; 47: 385-394.
54. Arriagada R., Dunant A., Pignon J.-P. i wsp. Long-term results of the International Adjuvant Lung Cancer Trial evaluating adjuvant cisplatinbased chemotherapy in resected lung cancer. J. Clin. Oncol. 2010; 28: 35-42.
55. Wrona A., Jassem J. Nowa klasyfikacja TNM w raku płuca. Onkol Prakt Klin 2009, 5: 250-260.
56. Jassem J. Combined chemotherapy and radiation in locally advanced non-small cell lung cancer. Lancet Oncol. 2001; 2: 335-342.
57. Rolland E., Le Chevalier T., Auperin A. i wsp. Sequential radiochemotherapy (RT-CT) versus radiotherapy alone (RT) and concomitant RT-CT versus RT alone in locally advanced non-small cell lung cancer (NSCLC): Two meta-anayles using individual patent data (IPD) from randomised clinical Trials (RCTs). J. Thorac. Oncol. 2007; 2 (supl.): 309.
58. Auperin A., Estelle R., Walter C. i wsp. Concomitant radiochemotherapy (RT-CT) versus sequential RT-CT in locally advanced non-small cell lung cancer (NSCLC): A meta-analysis using individual patent data (IPD) from randomised clinical trials. J. Thorac. Oncol. 2007; 2 (supl.): 310.
59. Rowell N.P., O'Rourke N. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst. Rev. 2004; 2: CD002140.
60. De Ruysscher D., Botterweck A., Dirx M. i wsp. Eligibility for concurrent chemotherapy and radiotherapy of locally advanced lung cancer patients: a prospective, population-based study. Ann. Oncol. 2009; 20: 98-102.
61. Machtay M., Hsu C., Komaki R. i wsp. Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced nonsmall- cell lung carcinoma: analysis of the Radiation Therapy Oncology Group (RTOG) experience. Int. J. Radiat. Oncol. Biol. Phys. 2005; 63: 667-671.
62. Vokes E.E., Herndon J.E., Kelley M.J. i wsp. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: Cancer and Leukemia Group B. J. Clin. Oncol. 2007; 25: 1698-1704.
63. Hanna N.H., Neubauer M., Yiannoutso C. i wsp. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-smallcell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J. Clin. Oncol. 2008; 26: 5755-5760.
64. NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: A systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J. Clin. Oncol. 2008; 26: 4617-4625.
65. Baggstrom M.Q., Stinchcombe T.E., Fried D.B. i wsp. Thirdgeneration chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis. J. Thorac. Oncol. 2007; 2: 845-853.
66. Goffin J., Lacchetti Ch., Ellis P.M. i wsp. First line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: A systematic review. J. Thorac. Oncol. 2010; 5: 260-274.
67. Delbaldo C., Michelis S., Syz N. i wsp. Benefits of adding a drug to a singleagent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA 2004; 292: 470-484.
68. Alberola V., Camps C., Provencio M. i wsp. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial. J. Clin. Oncol. 2003; 21: 3207-3213.
69. Hatem A.A., Elttar I., Loberizo Jr. F.R. i wsp. Third generation triplet cytotoxic chemotherapy in advanced non-small cell lung cancer: A systematic overview. Lung Cancer 2009; 64: 194-198.
70. Ardizzoni A., Boni L., Tiseo M. i wsp. Cisplatin versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data metaanalysis. J. Natl. Cancer Inst. 2007; 99: 847-857.
71. Kelly K., Crowley J., Bunn P.A. Jr. i wsp. Randomized phase III trial of paclitaxel plus carboplatin vs vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: a Southwest Oncology Group Trial. J. Clin. Oncol. 2001; 19: 3210-3218.
72. Schiller J.H., Harrington D., Belani C.P. i wsp. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N. Engl. J. Med. 2002; 346: 92-98.
73. Greco A.F., Gray, .JR., Thompson D.S. i wsp. Prospective randomized study of four novel chemotherapy regimens in patients with advanced nonsmall cell lung carcinoma. Cancer 2002; 95: 1279-1285.
74. Gao G., Jiang J., Liang X. i wsp. A meta-analysis of platinum plus gemcitabine or vinorelbine in the treatment of advanced non-small-cell lung cancer. Lung Cancer 2009; 65: 339-344.
75. Gronberg B.H., Bremnes R.M., Flotten O. i wsp. Phase III study by the Norwegian Lung Cancer Study Group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first line chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol. 2009; 27: 3217-3223.
76. Le Chevalier T., Scagliotti G., Natale R. i wsp. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 2005; 47: 69-80.
77. Douillard J.Y., Laporte S., Fossella F. i wsp. Comparison of docetaxel- and vinca alkaloid-based chemotherapy in the firstline treatment of advanced non-small cell lung cancer: a metaanalysis of seven randomized clinical trials. J. Thorac. Oncol. 2007; 2: 939-946.
78. Park J.O., Kim S.W., Ahn J.S. i wsp. Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer. J. Clin. Oncol. 2007; 25: 5233-5239.
79. von Plessen C., Bergman B., Andresen O. i wsp. Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer. Br. J. Cancer 2006; 95: 966-973.
80. Socinski M.A., Schell M.J., Peterman A. i wsp. A phase III trial comparing a defined duration of therapy vs continuous therapy followed by second line therapy in advanced stage IIIB/IV nonsmall cell lung cancer. J. Clin. Oncol. 2002; 20: 1335-1343.
81. Smith I.E., O'Brien M.E.R., Talbot D.C. i wsp. Duration of chemotherapy in advanced non-small cell lung cancer: a randomized trial of three vs six courses of mitomycin, vinblastine, and cisplatin. J. Clin. Oncol. 2001; 19: 1336-1343.
82. Brodowicz T., Krzakowski M., Zwitter M. i wsp. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer 2006; 52: 155-163.
83. Soon Y.Y., Stockler M.R., Askie L.M. i wsp. Duration of chemotherapy for advanced non-small-cell lung cancer: a systemic review and meta-analysis of randomized trials. J. Clin. Oncol. 2009; 20: 3277-3284.
84. da Silveira J.P., dos Santos L.V., Sasse E.Ch. i wsp. Optimal duration of first-line chemotherapy for advanced non-smallcell lung cancer: A systematic review with meta-analysis. Eur. J. Cancer 2009; 45: 601-607.
85. Fidias P., Dakhil S.R., Lyss A.P. i wsp. Phase III study of immediate versus delayed docetaxel after induction therapy with gemcitabine plus carboplatin in advanced non-small cell lung cancer: Updated report with survival. J. Clin. Oncol. 2009; 27: 591-598.
86. Ciuleanu T., Brodowicz T., Zielinski C. i wsp. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009; 374: 1432-1440.
87. Gatzemeier U., von Pavel J., Gottfried M. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small cell lung cancer. J. Clin. Oncol. 2000; 18: 3390-3399.
88. Langer C.J., Manola J., Bernardo P. i wsp. Cisplatin-based therapy for elderly patients with advanced non-small cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J. Natl. Cancer Inst. 2002; 94: 173-181.
89. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer: the Elderly Lung Cancer Vinorelbine Italian Study Group. J. Natl. Cancer Inst. 1999; 91: 66-72.
90. Frasci G., Lorusso V., Panza N. i wsp. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small cell lung cancer. J. Clin. Oncol. 2000; 18: 2529-2436.
91. Hainsworth J.D., Spigel D.R., Farley C. i wsp. Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer: a randomized phase 3 trial of the Minnie Pearl Cancer Research Network. Cancer 2007; 110: 2027-2034.
92. Lilenbaum R.C., Herndon J.E. 2nd, List M.A. i wsp. Singleagent versus combination chemotherapy in advanced nonsmall-cell lung cancer: the cancer and leukemia group B (study 9730). J. Clin. Oncol. 2005; 23: 190-196.
93. Barlesi F., Jacot W., Astoul P., Pujol J.-L. Second-line treatment for advanced non-small-cell lung cancer: a systematic review. Lung Cancer 2006; 51: 159-172.
94. Di Maio M., Chiodini P., Georgoulias V. i wsp. Meta-analysis of single agent chemotherapy compared with combination chemotherapy as a second-line treatment of advanced non-smallcell lung cancer. J. Clin. Oncol. 2009; 27: 1836-1843.
95. Shepherd F.A., Dancey J., Ramlau R. i wsp. Prospective randomized trial of docetaxel versus best supportive care in patients with non-smallcell lung cancer previously treated with platinum-based chemotherapy. J. Clin. Oncol. 2000; 18: 2095-2103.
96. Fossella F.V., DeVore R., Kerr R.N. i wsp. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J. Clin. Oncol. 2000; 18: 2354-2362.
97. Hanna N., Shepherd F.A., Fossella F.V. i wsp. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol. 2004; 22: 1589-1597.
98. Tassinari D., Scarpi E., Sartori S. i wsp. Second line treatments in nonsmall- cell lung cancer: A review of literature and metaanalysis of randomized clinical trials. Chest 2009; 135: 1596-609.
99. Di Maio M., Lama N., Morbiato A. i wsp. Clinical assessment of patients with advanced non-small-cell lung cancer eligible for secondline chemotherapy: A prognostic score from individual data of nine randomised trials. Eur. J. Cancer 2010; 46: 735-743.
100. Herbst R.S., Prager D., Hermann R. i wsp. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol. 2005; 23: 5892-5899.
101. Gatzemeier U., Pluzanska A., Szczesna A. i wsp. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J. Clin. Oncol. 2007; 25: 1545-1552.
102. Giaccone G., Herbst R.S., Manegold C. i wsp. Gefitynib in combination with gemcitabine and cisplatin in advanced non-smallcell lung cancer: a phase III trial-INTACT 1. J. Clin. Oncol. 2004; 22: 777-784.
103. Herbst R.S., Giaccone G., Schiller J.H. i wsp. Gefitynib in combinationwith paclitaxel and carboplatin in advanced nonsmall-cell lung cancer: a phase III trial-INTACT 2. J. Clin. Oncol. 2004; 22: 785-794.
104. Mok T.S., Wu Y.L., Thongprasert S. i wsp. Gefitynib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 2009; 361: 947-957.
105. Shepherd F.A., Pereira R.J., Ciuleanu T. i wsp. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 2005; 353: 123-132.
106. Bezjak A., Lee C.W., Ding K. i wsp. Quality-of-life outcomes for adjuvant chemotherapy in early-stage non-small-cell lung cancer: results from a randomized trial, JBR.10. J. Clin. Oncol. 2008; 26: 5052-5059.
107. Zhu C.Q., da Cunha Santos G., Ding K. i wsp. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J. Clin. Oncol. 2008; 26: 4268-4275.
108. Bradbury P.A., Tu D., Seymour L. i wsp. Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer. J. Natl. Cancer Inst. 2010; 102: 1-9.
109. Thatcher N., Chang A., Parikh P. i wsp. Gefitynib plus best supportive care in previously treated patients with refractory advanced nonsmall- cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366: 1527-1537.
110. Kim E.S., Hirsch V., Mok T. i wsp. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008; 372: 1809-1818.
111. Douillard J.-Y., Shepherd F.A., Hirsch V. i wsp. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-smallcell lung cancer: data from the randomized phase III INTEREST trial. J. Clin. Oncol. 2010; 28: 744-752.
112. Cappuzzo F., Ciuleanu T., Stelmakh L. i wsp. Efficacy and safety of erlotinib as first-line maintenance in NSCLC following non-progression with chemotherapy: results from the phase III SATURN study. Lancet Oncol. 2010 (w druku).
113. Takeda K., Hida T., Sato T. i wsp. Randomized phase III study of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a West Japan Thoracic Oncology Trial (WJTOG-0203). J. Clin. Oncol. 2010; 28: 753-7560.
114. Miller V.A., O'Connor P., Soh C. i wsp. A randomized, doubleblind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J. Clin. Oncol. 2009; 27 (supl.): 18s (abstrakt).
115. Pirker R., Pereira J.R., Szczesna A. i wsp. FLEX Study Team. Cetuximab plus chemotherapy in patients with advanced nonsmall- cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009; 373: 1525-1531.
116. Lynch T.J., Patel T., Dreisbach L. i wsp. Cetuximab and firstline taxane/ carboplatin chemotherapy in advanced non-smallcell lung cancer: results of the randomized multicenter phase III trial BMS099. J. Clin. Oncol. 2010; 28: 911-917.
117. O'Byrne K.J., Bondarenko I., Barrios C. i wsp. Molecular and clinical predictors of outcome for cetuximab in non-small cell lung cancer (NSCLC): Data from the FLEX study. J. Clin. Oncol. 2009; 27 (supl.): 15s (abstrakt).
118. Sandler A., Gray R., Perry M.C. i wsp. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 2006; 355: 2542-2550.
119. Sandler A.B., Kong G., Strickland D. i wsp. Treatment outcomes by tumor histology in Eastern Cooperative Group (ECOG) study E4599 of bevacizumab (BV) with paclitaxel/carboplatin (PC) for advanced non-small cell lung cancer (NSCLC). J. Thorac. Oncol. 2008; 3 (supl. 4): S283.
120. Reck M., von Pawel J., Zatloukal P. i wsp. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J. Clin. Oncol. 2009; 27: 1227-1234.
121. Sanjaykumar H., Chu D., Shenhong W. Risk of gastrointestinal perforation in patients with cancer treaded with bevacizumab: a metaanalysis. Lancet Oncol. 2009; 10: 559-568.
122. Nalluri S.R., Chu D., Keresztes R. i wsp. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizunab in cancer patients. JAMA 2008; 300: 2277-2285.
123. Muers M.F., Stephens R.J., Fisher P. i wsp. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet 2008; 371: 1685-1694.
124. Vogelzang N.J., Rusthoven J.J., Symanowski J. i wsp. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 2003; 21: 2636-2644.
125. Symanowski J., Rushoven J., Nguyen B. i wsp. Multiple regression analysis of prognostic variables for survival from the phase III study of pemetrexed + cisplatin in malignant pleural mesothelioma (abstrakt). Proc. Am. Soc. Clin. Oncol. 2003; 22: 647.
126. Jassem J., Ramlau R., Santoro A. i wsp. Pemetrexed plus best supportive care versus best supportive care in previously treated patients with advanced malignant pleural mesothelioma: A randomized phase III trial. J. Clin. Oncol. 2008; 26: 1698-1704.
127. Weder W., Stahel R.A., Bernhard J. i wsp. Multicenter trial of neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann. Oncol. 2007; 18: 1196-1202.
128. De Perrot M., Feld R., Cho B. i wsp. Trimodality therapy with induction chemotherapy followed bu extrapleural pneumonectomy and adjuvant high - dose hemithoracic radiation for malignant pleural mesothelioma. J. Clin. Oncol. 2009; 27: 1413-1418.
129. Krug L., Pass H., Rusch V. i wsp: Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J. Clin. Oncol. 2009; 27: 3007-3013.
130. Bokulbas S., Manegold C., Eberlein M. i wsp. Survival after trimodality therapy for malignant pleural mesothelioma: Radical pleurectomy, chemotherapy with cisplatin/pemetrexed and radiotherapy. Lung Cancer 2010 (w druku).